

National Radiology Data Registry

NMD Facility Screening Report, Jan-Mar 2020


Sample facility
(Facility ID: 100853)



nrdr.acr.org



NMD Facilities
Jan-Mar 2020




Black dots indicate NMD facilities that contributed data for this report


Facility ID=100853

NMD Facility Characteristics : March 2020


Facility type
100853: Community




Facility location
100853: Suburban



Census region
100853: Midwest



Annual procedure volume
100853: 5-10,000



Measure Definitions

Measure	Definition
All exams	Number of screening exams performed
Recall rate	Number and percent of screening exams with a BI-RADS assessment category of 0, 3, 4 or 5
Positive Predictive Value1 (PPV1)	Number and percent of screening exams with a BI-RADS assessment category of 0, 3, 4 or 5 and a tissue diagnosis of cancer within 12 months
Positive Predictive Value2 (PPV2)	Number and percent of screening exams with a recommendation for biopsy that resulted in a tissue diagnosis of cancer within 12 months of screening the exam
Positive Predictive Value3 (PPV3)	Number and percent of screening exams where a biopsy that was recommended and performed resulted in a tissue diagnosis of cancer within 12 months of screening the exam
Biopsy recommended	Number and percent of screening mammograms with either a BI-RADS assessment category of 4 or 5, or a BIRADS assessment category of 0 associated with category 4 or 5 on a diagnostic mammogram
Biopsy performed	Number and percent of screening exams with evidence of a biopsy
Biopsy result: Negative	Number and percent of biopsies where the patient had a histology result but did not have a tissue diagnosis of cancer within the next 12 months
Biopsy result: Postitive	Number and percent of biopsies where the patient had a tissue diagnosis of cancer within the next 12 months
Cancer Detection Rate (CDR) per 1000	Number of screening mammograms with a BI-RADS assessment category of 0, 4 or 5, total and per 1000, that had a tissue diagnosis of cancer within 12 months
Invasive Cancer Detection Rate (ICDR) per 1000	Number of screening mammograms with a BI-RADS assessment category of 0, 4 or 5, total and per 1000, that had a tissue diagnosis of invasive cancer within 12 months (calculated as Invasive cancer rate * CDR)
Ductal Carcinoma in Situ (DCIS)	Number and percent of cancers that were DCIS
Invasive cancer	Number and percent of cancers that were invasive

To learn more about the Qualified Clinical Data Registry (QCDR) option and ACRad measures, please click below
<http://www.acr.org/Quality-Safety/National-Radiology-Data-Registry/Qualified-Clinical-Data-Registry>

Measure Definitions

Measure	Definition
Minimal cancer	Number and percent of cancers that were DCIS or had a tumor size of 10 mm or less
Nodal status - Negative	Number and percent of invasive cancers where nodal status was negative
Nodal status - Positive	Number and percent of invasive cancers where nodal status was positive
Tumor size	Number and percent of tumors by size, in mm, where size is reported (Tumor size is set to zero for all DCIS lesions)
Tumor stage	Number and percent of tumors by stage, where stage is reported
Inappropriate use of BI-RADS 3	Number and percent of screening exams with a BI-RADS assessment category of 3
Early cancer detection rate (ACRad 35)	Number of and percent of cancers that were (a) invasive and node negative, OR (b) invasive and ≤ 10 mm, OR (c) DCIS, detected at screening mammography.

Distributions of facilities

This report includes charts that display the distribution of measures across facilities. Each facility contributes one point to each chart - the value of the measure for all exams performed at the facility during the year indicated in the title.


Histograms

For each measure, there is a histogram that shows the distribution of the measure across all facilities in NMD, with a smoothed distribution overlaid on the histogram. The rate for your facility is displayed as a vertical line.

Boxplots

For each measure, there is a graph of boxplots comparing facilities across various categories. The illustration below will help you interpret the boxplot. The rate for your facility is displayed as a horizontal line.

Box-and-whiskers Plot



SAS Institute Inc., SAS 9.1.3 Help and Documentation, Cary, NC: SAS Institute Inc., 2002-2004.

***Section 1: Outcome measures and demographic data for exams
performed during January-December 2019 with follow-up through
March 2020***

*(Report on screening exams performed during January 2020 - March 2020 at the facility are
available in Section 2)*

Abnormal Interpretations and Cancers for Screening Mammography
January 2019 - December 2019: Comparison to all NMD facilities

	Facility 100853		NMD (N=205)	
Measure	Rate	(Num-Den)	Rate	(Num-Den)
All exams		9,482		3,102,964
Recall rate	15.32%	(1,453/9,482)	10.07%	(312,616/3,102,964)
PPV1	5.51%	(43/780)	4.04%	(12,638/312,616)
PPV2	22.36%	(36/161)	20.76%	(10,679/51,448)
PPV3	28.57%	(36/126)	27.79%	(10,679/38,423)
Biopsy recommended	1.70%	(161/9,482)	1.66%	(51,448/3,102,964)
Biopsy performed	3.55%	(337/9,482)	1.49%	(46,200/3,102,964)
Biopsy result: Negative	69.35%	(215/310)	69.56%	(28,879/41,517)
Biopsy result: Positive	30.65%	(95/310)	30.44%	(12,638/41,517)
CDR per 1000	10.02	(95/9,482)	4.07	(12,638/3,102,964)
ICDR per 1000	8.12	(77/9,482)	3.10	(9,633/3,102,964)
Ductal carcinoma in-situ	18.95%	(18/95)	23.78%	(3,005/12,638)
Invasive cancer	81.05%	(77/95)	76.22%	(9,633/12,638)
Minimal cancer	58.97%	(23/39)	36.93%	(4,667/12,638)
Nodal status: Negative	14.29%	(11/77)	21.09%	(2,032/9,633)
Nodal status: Positive	5.19%	(4/77)	2.96%	(285/9,633)
Tumor size: 1-5mm	6.67%	(2/30)	16.17%	(566/3,501)
Tumor size: 6-10mm	16.67%	(5/30)	32.50%	(1,138/3,501)
Tumor size: 11-15mm	33.33%	(10/30)	23.91%	(837/3,501)
Tumor size: 16-20mm	23.33%	(7/30)	11.17%	(391/3,501)
Tumor size: >20mm	20.00%	(6/30)	16.25%	(569/3,501)
Tumor stage: 0	40.00%	(6/15)	16.62%	(261/1,570)
Tumor stage: I	33.33%	(5/15)	66.50%	(1,044/1,570)
Tumor stage: II	13.33%	(2/15)	14.90%	(234/1,570)
Tumor stage: III	13.33%	(2/15)	1.85%	(29/1,570)

***Abnormal Interpretations and Cancers for Screening Mammography
January 2019 - December 2019: Comparison to all NMD facilities***

	Facility 100853		NMD (N=205)	
Measure	Rate	(Num-Den)	Rate	(Num-Den)
Tumor stage: IV		(./15)	0.13%	(2/1,570)
Early cancer detection rate (ACRad 35)	33.68%	(32/95)	48.55%	(6,136/12,638)

Abnormal Interpretations and Cancers for Screening Mammography
January 2019 - December 2019: Comparison to similar facilities

	Facility 100853		Community (N=98)	
Measure	Rate	(Num-Den)	Rate	(Num-Den)
All exams		9,482		1,363,320
Recall rate	15.32%	(1,453/9,482)	10.70%	(145,834/1,363,320)
PPV1	5.51%	(43/780)	3.83%	(5,579/145,834)
PPV2	22.36%	(36/161)	20.35%	(4,771/23,439)
PPV3	28.57%	(36/126)	28.84%	(4,771/16,545)
Biopsy recommended	1.70%	(161/9,482)	1.72%	(23,439/1,363,320)
Biopsy performed	3.55%	(337/9,482)	1.47%	(19,982/1,363,320)
Biopsy result: Negative	69.35%	(215/310)	69.42%	(12,664/18,243)
Biopsy result: Positive	30.65%	(95/310)	30.58%	(5,579/18,243)
CDR per 1000	10.02	(95/9,482)	4.09	(5,579/1,363,320)
ICDR per 1000	8.12	(77/9,482)	3.11	(4,239/1,363,320)
Ductal carcinoma in-situ	18.95%	(18/95)	24.02%	(1,340/5,579)
Invasive cancer	81.05%	(77/95)	75.98%	(4,239/5,579)
Minimal cancer	58.97%	(23/39)	35.97%	(2,007/5,579)
Nodal status: Negative	14.29%	(11/77)	23.76%	(1,007/4,239)
Nodal status: Positive	5.19%	(4/77)	3.42%	(145/4,239)
Tumor size: 1-5mm	6.67%	(2/30)	15.81%	(247/1,562)
Tumor size: 6-10mm	16.67%	(5/30)	30.99%	(484/1,562)
Tumor size: 11-15mm	33.33%	(10/30)	25.54%	(399/1,562)
Tumor size: 16-20mm	23.33%	(7/30)	13.57%	(212/1,562)
Tumor size: >20mm	20.00%	(6/30)	14.08%	(220/1,562)
Tumor stage: 0	40.00%	(6/15)	19.32%	(154/797)
Tumor stage: I	33.33%	(5/15)	66.00%	(526/797)
Tumor stage: II	13.33%	(2/15)	12.80%	(102/797)
Tumor stage: III	13.33%	(2/15)	1.63%	(13/797)

***Abnormal Interpretations and Cancers for Screening Mammography
January 2019 - December 2019: Comparison to similar facilities***

	Facility 100853		Community (N=98)	
Measure	Rate	(Num-Den)	Rate	(Num-Den)
Tumor stage: IV		(./15)	0.25%	(2/797)
Early cancer detection rate (ACRad 35)	33.68%	(32/95)	48.88%	(2,727/5,579)





Abnormal Interpretations and Cancers for Screening Mammography
January 2019 - December 2019: Comparison to similar facilities

	Facility 100853		Suburban (N=71)		Midwest (N=53)	
Measure	Rate	(Num-Den)	Rate	(Num-Den)	Rate	(Num-Den)
All exams		9,482		1,019,395		705,033
Recall rate	15.32%	(1,453/9,482)	11.21%	(114,275/1,019,395)	8.70%	(61,337/705,033)
PPV1	5.51%	(43/780)	3.35%	(3,825/114,275)	5.01%	(3,071/61,337)
PPV2	22.36%	(36/161)	18.58%	(3,201/17,232)	24.96%	(2,366/9,479)
PPV3	28.57%	(36/126)	26.98%	(3,201/11,865)	31.36%	(2,366/7,544)
Biopsy recommended	1.70%	(161/9,482)	1.69%	(17,232/1,019,395)	1.34%	(9,479/705,033)
Biopsy performed	3.55%	(337/9,482)	1.44%	(14,651/1,019,395)	1.41%	(9,975/705,033)
Biopsy result: Negative	69.35%	(215/310)	69.78%	(8,834/12,659)	67.85%	(6,482/9,553)
Biopsy result: Positive	30.65%	(95/310)	30.22%	(3,825/12,659)	32.15%	(3,071/9,553)
CDR per 1000	10.02	(95/9,482)	3.75	(3,825/1,019,395)	4.36	(3,071/705,033)
ICDR per 1000	8.12	(77/9,482)	2.83	(2,883/1,019,395)	3.33	(2,349/705,033)
Ductal carcinoma in-situ	18.95%	(18/95)	24.63%	(942/3,825)	23.51%	(722/3,071)
Invasive cancer	81.05%	(77/95)	75.37%	(2,883/3,825)	76.49%	(2,349/3,071)
Minimal cancer	58.97%	(23/39)	40.03%	(1,531/3,825)	38.39%	(1,179/3,071)
Nodal status: Negative	14.29%	(11/77)	21.92%	(632/2,883)	28.91%	(679/2,349)
Nodal status: Positive	5.19%	(4/77)	3.36%	(97/2,883)	5.49%	(129/2,349)
Tumor size: 1-5mm	6.67%	(2/30)	19.27%	(227/1,178)	17.13%	(174/1,016)
Tumor size: 6-10mm	16.67%	(5/30)	32.17%	(379/1,178)	32.28%	(328/1,016)
Tumor size: 11-15mm	33.33%	(10/30)	24.96%	(294/1,178)	26.08%	(265/1,016)
Tumor size: 16-20mm	23.33%	(7/30)	10.95%	(129/1,178)	12.11%	(123/1,016)
Tumor size: >20mm	20.00%	(6/30)	12.65%	(149/1,178)	12.40%	(126/1,016)
Tumor stage: 0	40.00%	(6/15)	16.36%	(81/495)	13.41%	(92/686)
Tumor stage: I	33.33%	(5/15)	65.86%	(326/495)	69.97%	(480/686)
Tumor stage: II	13.33%	(2/15)	16.36%	(81/495)	14.43%	(99/686)
Tumor stage: III	13.33%	(2/15)	1.41%	(7/495)	2.19%	(15/686)

***Abnormal Interpretations and Cancers for Screening Mammography
January 2019 - December 2019: Comparison to similar facilities***


	Facility 100853		Suburban (N=71)		Midwest (N=53)	
Measure	Rate	(Num-Den)	Rate	(Num-Den)	Rate	(Num-Den)
Tumor stage: IV		(./15)		(./495)		(./686)
Early cancer detection rate (ACRad 35)	33.68%	(32/95)	51.56%	(1,972/3,825)	53.60%	(1,646/3,071)

Abnormal Interpretations and Cancers for Screening Mammography
January 2019 - December 2019: Comparisons




**Abnormal Interpretations and Cancers for Screening Mammography
January 2019 - December 2019: Comparisons**



Biopsy Results





Early Cancer Detection Rate (ECDR)





***Distribution of Recall Rate
January 2019 - December 2019***





Distribution of PPV2 **January 2019 - December 2019**





***Distribution of CDR per 1000
January 2019 - December 2019***





Distribution of PPV1 ***January 2019 - December 2019***





Distribution of PPV3 **January 2019 - December 2019**





Distribution of biopsy positives January 2019 - December 2019





***Distribution of Ductal carcinoma in-situ
January 2019 - December 2019***





Distribution of Invasive Cancer January 2019 - December 2019



Distribution of Minimal Cancer January 2019 - December 2019




Distribution of Early Cancer Detection Rate **January 2019 - December 2019**



Trends: Abnormal Interpretations and Cancers for Screening Mammography
January 2019 - December 2019


Recall rate




Each data point represents 12-month period ending December 31st.




PPV2



Each data point represents 12-month period ending December 31st.




CDR per 1000




Each data point represents 12-month period ending December 31st.



PPV1




Each data point represents 12-month period ending December 31st.



Trends: Abnormal Interpretations and Cancers for Screening Mammography
January 2019 - December 2019


PPV3




Each data point represents 12-month period ending December 31st.




Biopsy result: Positive



Each data point represents 12-month period ending December 31st.




Ductal carcinoma in-situ




Each data point represents 12-month period ending December 31st.



Invasive cancer




Each data point represents 12-month period ending December 31st.



Trends: Abnormal Interpretations and Cancers for Screening Mammography
January 2019 - December 2019


Minimal cancer



Each data point represents 12-month period ending December 31st.

— Facility 100853	- - - Community (N= 98)
- - - Suburban (N=71)	- - - Midwest (N= 53)
- - - 5-10,000 procs (N=115)	— NMD (N=205)

Early cancer detection rate (ACRad 35)



Each data point represents 12-month period ending December 31st.

— Facility 100853	- - - Community (N= 98)
- - - Suburban (N=71)	- - - Midwest (N= 53)
- - - 5-10,000 procs (N=115)	— NMD (N=205)

Clinical Demographics for Screening Mammography Examinations
January 2019 - December 2019: Comparison to all NMD facilities

	Facility 100853		NMD (N=205)	
Measure	Rate	(Num-Den)	Rate	(Num-Den)
Age: 0-29	0.13%	(12/9,470)	0.04%	(1,359/3,098,848)
Age: 30-39	2.13%	(202/9,470)	1.03%	(31,770/3,098,848)
Age: 40-49	21.62%	(2,047/9,470)	20.56%	(637,167/3,098,848)
Age: 50-59	27.04%	(2,561/9,470)	27.86%	(863,361/3,098,848)
Age: 60-69	28.15%	(2,666/9,470)	28.92%	(896,290/3,098,848)
Age: 70-79	16.76%	(1,587/9,470)	17.63%	(546,294/3,098,848)
Age: 80 and older	4.17%	(395/9,470)	3.96%	(122,607/3,098,848)
Assessment category: 0	9.63%	(913/9,482)	9.78%	(303,331/3,102,964)
Assessment category: 1	48.38%	(4,587/9,482)	54.73%	(1,698,292/3,102,964)
Assessment category: 2	36.25%	(3,437/9,482)	35.19%	(1,092,046/3,102,964)
Inappropriate use of BI-RADS 3	3.34%	(317/9,482)	0.22%	(6,692/3,102,964)
Assessment category: 4	2.11%	(200/9,482)	0.07%	(2,299/3,102,964)
Assessment category: 5	0.24%	(23/9,482)	0.01%	(294/3,102,964)
Breast density: 0-25%	7.47%	(698/9,344)	7.68%	(236,717/3,081,537)
Breast density: 25-50%	48.88%	(4,567/9,344)	49.74%	(1,532,883/3,081,537)
Breast density: 50-75%	34.58%	(3,231/9,344)	34.19%	(1,053,725/3,081,537)
Breast density: >75%	5.34%	(499/9,344)	5.11%	(157,318/3,081,537)
Breast density: Unknown	3.74%	(349/9,344)	3.27%	(100,894/3,081,537)
Personal history of breast cancer	8.39%	(492/5,864)	5.70%	(112,952/1,982,689)
Family history of breast cancer	17.19%	(577/3,357)	17.71%	(185,057/1,044,876)
Symptoms reported	2.60%	(92/3,538)	0.04%	(472/1,326,463)

Clinical Demographics for Screening Mammography Examinations
January 2019 - December 2019: Similar facilities


	Facility 100853		Community (N=98)	
Measure	Rate	(Num-Den)	Rate	(Num-Den)
Age: 0-29	0.13%	(12/9,470)	0.05%	(684/1,363,254)
Age: 30-39	2.13%	(202/9,470)	0.95%	(12,899/1,363,254)
Age: 40-49	21.62%	(2,047/9,470)	19.96%	(272,113/1,363,254)
Age: 50-59	27.04%	(2,561/9,470)	27.60%	(376,320/1,363,254)
Age: 60-69	28.15%	(2,666/9,470)	29.12%	(397,007/1,363,254)
Age: 70-79	16.76%	(1,587/9,470)	18.06%	(246,167/1,363,254)
Age: 80 and older	4.17%	(395/9,470)	4.26%	(58,064/1,363,254)
Assessment category: 0	9.63%	(913/9,482)	10.39%	(141,601/1,363,320)
Assessment category: 1	48.38%	(4,587/9,482)	54.84%	(747,662/1,363,320)
Assessment category: 2	36.25%	(3,437/9,482)	34.46%	(469,820/1,363,320)
Inappropriate use of BI-RADS 3	3.34%	(317/9,482)	0.23%	(3,089/1,363,320)
Assessment category: 4	2.11%	(200/9,482)	0.08%	(1,025/1,363,320)
Assessment category: 5	0.24%	(23/9,482)	0.01%	(119/1,363,320)
Breast density: 0-25%	7.47%	(698/9,344)	7.80%	(105,867/1,357,736)
Breast density: 25-50%	48.88%	(4,567/9,344)	50.05%	(679,508/1,357,736)
Breast density: 50-75%	34.58%	(3,231/9,344)	34.40%	(467,066/1,357,736)
Breast density: >75%	5.34%	(499/9,344)	4.72%	(64,119/1,357,736)
Breast density: Unknown	3.74%	(349/9,344)	3.03%	(41,176/1,357,736)
Personal history of breast cancer	8.39%	(492/5,864)	6.26%	(56,184/896,973)
Family history of breast cancer	17.19%	(577/3,357)	15.82%	(112,100/708,690)
Symptoms reported	2.60%	(92/3,538)	0.06%	(279/490,349)

Clinical Demographics for Screening Mammography Examinations
January 2019 - December 2019: Similar facilities


	Facility 100853		Suburban (N=71)		Midwest (N=53)	
Measure	Rate	(Num-Den)	Rate	(Num-Den)	Rate	(Num-Den)
Age: 0-29	0.13%	(12/9,470)	0.06%	(623/1,015,345)	0.04%	(251/704,969)
Age: 30-39	2.13%	(202/9,470)	1.02%	(10,385/1,015,345)	1.05%	(7,433/704,969)
Age: 40-49	21.62%	(2,047/9,470)	20.18%	(204,876/1,015,345)	21.04%	(148,325/704,969)
Age: 50-59	27.04%	(2,561/9,470)	27.78%	(282,064/1,015,345)	28.56%	(201,312/704,969)
Age: 60-69	28.15%	(2,666/9,470)	29.05%	(294,956/1,015,345)	28.82%	(203,170/704,969)
Age: 70-79	16.76%	(1,587/9,470)	17.71%	(179,854/1,015,345)	16.62%	(117,148/704,969)
Age: 80 and older	4.17%	(395/9,470)	4.19%	(42,587/1,015,345)	3.88%	(27,330/704,969)
Assessment category: 0	9.63%	(913/9,482)	10.70%	(109,104/1,019,395)	8.45%	(59,559/705,033)
Assessment category: 1	48.38%	(4,587/9,482)	49.49%	(504,494/1,019,395)	57.91%	(408,260/705,033)
Assessment category: 2	36.25%	(3,437/9,482)	39.30%	(400,622/1,019,395)	33.39%	(235,434/705,033)
Inappropriate use of BI-RADS 3	3.34%	(317/9,482)	0.38%	(3,831/1,019,395)	0.18%	(1,262/705,033)
Assessment category: 4	2.11%	(200/9,482)	0.12%	(1,181/1,019,395)	0.06%	(450/705,033)
Assessment category: 5	0.24%	(23/9,482)	0.02%	(159/1,019,395)	0.01%	(66/705,033)
Breast density: 0-25%	7.47%	(698/9,344)	7.26%	(73,475/1,011,978)	7.48%	(52,702/704,359)
Breast density: 25-50%	48.88%	(4,567/9,344)	49.24%	(498,320/1,011,978)	51.31%	(361,382/704,359)
Breast density: 50-75%	34.58%	(3,231/9,344)	31.87%	(322,506/1,011,978)	36.56%	(257,543/704,359)
Breast density: >75%	5.34%	(499/9,344)	5.26%	(53,187/1,011,978)	4.18%	(29,438/704,359)
Breast density: Unknown	3.74%	(349/9,344)	6.37%	(64,490/1,011,978)	0.47%	(3,294/704,359)
Personal history of breast cancer	8.39%	(492/5,864)	5.43%	(39,945/736,207)	6.24%	(30,572/489,607)
Family history of breast cancer	17.19%	(577/3,357)	21.44%	(81,859/381,737)	23.15%	(57,871/249,940)
Symptoms reported	2.60%	(92/3,538)	0.10%	(444/444,621)	0.04%	(113/252,695)

Clinical Demographics for Screening Mammography
January 2019 - December 2019: Comparisons

Age Distribution




Assessment Categories




***Clinical Demographics for Screening Mammography
January 2019 - December 2019: Comparisons***

Breast Density



History



Section 2: Report on screening exams performed during Jan-Mar 2020

Abnormal Interpretations and Cancers for Screening Mammography
January 2020 - March 2020: Comparison to all NMD facilities

	Facility 100853		NMD (N=205)	
Measure	Rate	(Num-Den)	Rate	(Num-Den)
All exams		935		281,537
Recall rate	15.94%	(149/935)	9.87%	(27,782/281,537)
PPV1	5.19%	(4/77)	3.42%	(949/27,782)
PPV2	21.43%	(3/14)	20.16%	(854/4,236)
PPV3	33.33%	(3/9)	30.75%	(854/2,777)
Biopsy recommended	1.50%	(14/935)	1.50%	(4,236/281,537)
Biopsy performed	3.42%	(32/935)	1.16%	(3,273/281,537)
Biopsy result: Negative	56.25%	(18/32)	68.01%	(2,018/2,967)
Biopsy result: Positive	43.75%	(14/32)	31.99%	(949/2,967)
CDR per 1000	14.97	(14/935)	3.37	(949/281,537)
ICDR per 1000	9.63	(9/935)	2.51	(708/281,537)
Ductal carcinoma in-situ	35.71%	(5/14)	25.40%	(241/949)
Invasive cancer	64.29%	(9/14)	74.60%	(708/949)
Minimal cancer	75.00%	(6/8)	33.19%	(315/949)
Nodal status: Negative	22.22%	(2/9)	9.46%	(67/708)
Nodal status: Positive		(./9)	1.41%	(10/708)
Tumor size: 1-5mm		(./3)	16.98%	(27/159)
Tumor size: 6-10mm	33.33%	(1/3)	36.48%	(58/159)
Tumor size: 11-15mm	33.33%	(1/3)	20.13%	(32/159)
Tumor size: 16-20mm	33.33%	(1/3)	15.72%	(25/159)
Tumor size: >20mm		(./3)	10.69%	(17/159)
Tumor stage: 0		(./1)	18.42%	(7/38)
Tumor stage: I	100.00%	(1/1)	63.16%	(24/38)
Tumor stage: II		(./1)	13.16%	(5/38)
Tumor stage: III		(./1)	2.63%	(1/38)

***Abnormal Interpretations and Cancers for Screening Mammography
January 2020 - March 2020: Comparison to all NMD facilities***

	Facility 100853		NMD (N=205)	
Measure	Rate	(Num-Den)	Rate	(Num-Den)
Tumor stage: IV		(./1)	2.63%	(1/38)
Early cancer detection rate (ACRad 35)	57.14%	(8/14)	39.09%	(371/949)

Abnormal Interpretations and Cancers for Screening Mammography
January 2020 - March 2020: Similar facilities

	Facility 100853		Community (N=98)	
Measure	Rate	(Num-Den)	Rate	(Num-Den)
All exams		935		131,739
Recall rate	15.94%	(149/935)	10.14%	(13,361/131,739)
PPV1	5.19%	(4/77)	3.61%	(483/13,361)
PPV2	21.43%	(3/14)	20.55%	(438/2,131)
PPV3	33.33%	(3/9)	31.60%	(438/1,386)
Biopsy recommended	1.50%	(14/935)	1.62%	(2,131/131,739)
Biopsy performed	3.42%	(32/935)	1.24%	(1,628/131,739)
Biopsy result: Negative	56.25%	(18/32)	67.12%	(986/1,469)
Biopsy result: Positive	43.75%	(14/32)	32.88%	(483/1,469)
CDR per 1000	14.97	(14/935)	3.67	(483/131,739)
ICDR per 1000	9.63	(9/935)	2.79	(367/131,739)
Ductal carcinoma in-situ	35.71%	(5/14)	24.02%	(116/483)
Invasive cancer	64.29%	(9/14)	75.98%	(367/483)
Minimal cancer	75.00%	(6/8)	30.43%	(147/483)
Nodal status: Negative	22.22%	(2/9)	9.26%	(34/367)
Nodal status: Positive		(./9)	2.45%	(9/367)
Tumor size: 1-5mm		(./3)	21.88%	(14/64)
Tumor size: 6-10mm	33.33%	(1/3)	32.81%	(21/64)
Tumor size: 11-15mm	33.33%	(1/3)	17.19%	(11/64)
Tumor size: 16-20mm	33.33%	(1/3)	18.75%	(12/64)
Tumor size: >20mm		(./3)	9.38%	(6/64)
Tumor stage: 0		(./1)		(./16)
Tumor stage: I	100.00%	(1/1)	75.00%	(12/16)
Tumor stage: II		(./1)	12.50%	(2/16)
Tumor stage: III		(./1)	6.25%	(1/16)

***Abnormal Interpretations and Cancers for Screening Mammography
January 2020 - March 2020: Similar facilities***

	Facility 100853		Community (N=98)	
Measure	Rate	(Num-Den)	Rate	(Num-Den)
Tumor stage: IV		(./1)	6.25%	(1/16)
Early cancer detection rate (ACRad 35)	57.14%	(8/14)	36.02%	(174/483)





Abnormal Interpretations and Cancers for Screening Mammography
January 2020 - March 2020: Similar facilities

	Facility 100853		Suburban (N=71)		Midwest (N=53)	
Measure	Rate	(Num-Den)	Rate	(Num-Den)	Rate	(Num-Den)
All exams		935		95,589		49,203
Recall rate	15.94%	(149/935)	10.35%	(9,897/95,589)	8.87%	(4,364/49,203)
PPV1	5.19%	(4/77)	2.64%	(261/9,897)	3.80%	(166/4,364)
PPV2	21.43%	(3/14)	17.32%	(237/1,368)	26.24%	(143/545)
PPV3	33.33%	(3/9)	29.92%	(237/792)	36.67%	(143/390)
Biopsy recommended	1.50%	(14/935)	1.43%	(1,368/95,589)	1.11%	(545/49,203)
Biopsy performed	3.42%	(32/935)	1.00%	(953/95,589)	0.99%	(485/49,203)
Biopsy result: Negative	56.25%	(18/32)	69.22%	(587/848)	65.42%	(314/480)
Biopsy result: Positive	43.75%	(14/32)	30.78%	(261/848)	34.58%	(166/480)
CDR per 1000	14.97	(14/935)	2.73	(261/95,589)	3.37	(166/49,203)
ICDR per 1000	9.63	(9/935)	1.99	(190/95,589)	2.85	(140/49,203)
Ductal carcinoma in-situ	35.71%	(5/14)	27.20%	(71/261)	15.66%	(26/166)
Invasive cancer	64.29%	(9/14)	72.80%	(190/261)	84.34%	(140/166)
Minimal cancer	75.00%	(6/8)	35.63%	(93/261)	32.53%	(54/166)
Nodal status: Negative	22.22%	(2/9)	6.32%	(12/190)	12.86%	(18/140)
Nodal status: Positive		(./9)	1.58%	(3/190)	2.86%	(4/140)
Tumor size: 1-5mm		(./3)	5.08%	(3/59)	14.89%	(7/47)
Tumor size: 6-10mm	33.33%	(1/3)	38.98%	(23/59)	48.94%	(23/47)
Tumor size: 11-15mm	33.33%	(1/3)	25.42%	(15/59)	12.77%	(6/47)
Tumor size: 16-20mm	33.33%	(1/3)	16.95%	(10/59)	14.89%	(7/47)
Tumor size: >20mm		(./3)	13.56%	(8/59)	8.51%	(4/47)
Tumor stage: 0		(./1)		(./5)	6.90%	(2/29)
Tumor stage: I	100.00%	(1/1)	60.00%	(3/5)	75.86%	(22/29)
Tumor stage: II		(./1)		(./5)	13.79%	(4/29)
Tumor stage: III		(./1)	20.00%	(1/5)	3.45%	(1/29)

***Abnormal Interpretations and Cancers for Screening Mammography
January 2020 - March 2020: Similar facilities***


	Facility 100853		Suburban (N=71)		Midwest (N=53)	
Measure	Rate	(Num-Den)	Rate	(Num-Den)	Rate	(Num-Den)
Tumor stage: IV		(./1)	20.00%	(1/5)		(./29)
Early cancer detection rate (ACRad 35)	57.14%	(8/14)	39.08%	(102/261)	39.16%	(65/166)

**Abnormal Interpretations and Cancers for Screening Mammography
January 2020 - March 2020: Comparisons**




***Abnormal Interpretations and Cancers for Screening Mammography
January 2020 - March 2020: Comparisons***



Biopsy Results





***Abnormal Interpretations and Cancers for Screening Mammography
January 2020 - March 2020: Comparisons***





Distribution of Recall Rate **January 2020 - March 2020**





Distribution of PPV2 **January 2020 - March 2020**





Distribution of CDR per 1000
January 2020 - March 2020





Distribution of PPV1 ***January 2020 - March 2020***





**Distribution of PPV3
January 2020 - March 2020**





Distribution of biopsy positives **January 2020 - March 2020**





***Distribution of Ductal carcinoma in-situ
January 2020 - March 2020***





Distribution of Invasive Cancer January 2020 - March 2020



Distribution of Minimal Cancer **January 2020 - March 2020**



Distribution of Early Cancer Detection Rate January 2020 - March 2020



Clinical Demographics for Screening Mammography Examinations
January 2020 - March 2020: Comparison to all NMD facilities

	Facility 100853		NMD (N=205)	
Measure	Rate	(Num-Den)	Rate	(Num-Den)
Age: 0-29	0.21%	(2/935)	0.05%	(147/281,537)
Age: 30-39	2.57%	(24/935)	1.21%	(3,411/281,537)
Age: 40-49	23.42%	(219/935)	21.39%	(60,215/281,537)
Age: 50-59	25.24%	(236/935)	28.00%	(78,828/281,537)
Age: 60-69	26.63%	(249/935)	28.36%	(79,852/281,537)
Age: 70-79	17.75%	(166/935)	17.30%	(48,695/281,537)
Age: 80 and older	4.17%	(39/935)	3.69%	(10,389/281,537)
Assessment category: 0	8.88%	(83/935)	9.44%	(26,570/281,537)
Assessment category: 1	47.59%	(445/935)	56.67%	(159,536/281,537)
Assessment category: 2	36.36%	(340/935)	33.47%	(94,219/281,537)
Inappropriate use of BI-RADS 3	4.39%	(41/935)	0.30%	(851/281,537)
Assessment category: 4	2.35%	(22/935)	0.11%	(315/281,537)
Assessment category: 5	0.32%	(3/935)	0.02%	(46/281,537)
Breast density: 0-25%	5.77%	(53/918)	7.25%	(20,174/278,302)
Breast density: 25-50%	43.79%	(402/918)	46.51%	(129,442/278,302)
Breast density: 50-75%	39.76%	(365/918)	35.60%	(99,074/278,302)
Breast density: >75%	4.79%	(44/918)	5.14%	(14,317/278,302)
Breast density: Unknown	5.88%	(54/918)	5.50%	(15,295/278,302)
Personal history of breast cancer	9.53%	(41/430)	5.40%	(7,986/147,945)
Family history of breast cancer	16.00%	(68/425)	13.61%	(17,366/127,624)
Symptoms reported	1.71%	(4/234)	0.09%	(80/89,568)

Clinical Demographics for Screening Mammography Examinations
January 2020 - March 2020: Similar facilities


	Facility 100853		Community (N=98)	
Measure	Rate	(Num-Den)	Rate	(Num-Den)
Age: 0-29	0.21%	(2/935)	0.07%	(88/131,739)
Age: 30-39	2.57%	(24/935)	1.09%	(1,430/131,739)
Age: 40-49	23.42%	(219/935)	20.63%	(27,183/131,739)
Age: 50-59	25.24%	(236/935)	27.79%	(36,607/131,739)
Age: 60-69	26.63%	(249/935)	28.57%	(37,640/131,739)
Age: 70-79	17.75%	(166/935)	17.82%	(23,470/131,739)
Age: 80 and older	4.17%	(39/935)	4.04%	(5,321/131,739)
Assessment category: 0	8.88%	(83/935)	9.69%	(12,765/131,739)
Assessment category: 1	47.59%	(445/935)	55.15%	(72,655/131,739)
Assessment category: 2	36.36%	(340/935)	34.71%	(45,723/131,739)
Inappropriate use of BI-RADS 3	4.39%	(41/935)	0.32%	(423/131,739)
Assessment category: 4	2.35%	(22/935)	0.12%	(152/131,739)
Assessment category: 5	0.32%	(3/935)	0.02%	(21/131,739)
Breast density: 0-25%	5.77%	(53/918)	7.34%	(9,639/131,375)
Breast density: 25-50%	43.79%	(402/918)	46.80%	(61,477/131,375)
Breast density: 50-75%	39.76%	(365/918)	36.46%	(47,896/131,375)
Breast density: >75%	4.79%	(44/918)	5.02%	(6,600/131,375)
Breast density: Unknown	5.88%	(54/918)	4.39%	(5,763/131,375)
Personal history of breast cancer	9.53%	(41/430)	6.92%	(4,183/60,462)
Family history of breast cancer	16.00%	(68/425)	12.66%	(10,873/85,887)
Symptoms reported	1.71%	(4/234)	0.12%	(39/31,756)

Clinical Demographics for Screening Mammography Examinations
January 2020 - March 2020: Similar facilities


	Facility 100853		Suburban (N=71)		Midwest (N=53)	
Measure	Rate	(Num-Den)	Rate	(Num-Den)	Rate	(Num-Den)
Age: 0-29	0.21%	(2/935)	0.10%	(98/95,589)	0.02%	(9/49,203)
Age: 30-39	2.57%	(24/935)	1.39%	(1,325/95,589)	1.12%	(553/49,203)
Age: 40-49	23.42%	(219/935)	20.98%	(20,057/95,589)	21.51%	(10,582/49,203)
Age: 50-59	25.24%	(236/935)	27.62%	(26,399/95,589)	28.31%	(13,929/49,203)
Age: 60-69	26.63%	(249/935)	28.71%	(27,448/95,589)	28.65%	(14,098/49,203)
Age: 70-79	17.75%	(166/935)	17.47%	(16,695/95,589)	16.55%	(8,143/49,203)
Age: 80 and older	4.17%	(39/935)	3.73%	(3,567/95,589)	3.84%	(1,889/49,203)
Assessment category: 0	8.88%	(83/935)	9.52%	(9,101/95,589)	8.32%	(4,093/49,203)
Assessment category: 1	47.59%	(445/935)	50.59%	(48,357/95,589)	61.24%	(30,130/49,203)
Assessment category: 2	36.36%	(340/935)	39.06%	(37,335/95,589)	29.89%	(14,709/49,203)
Inappropriate use of BI-RADS 3	4.39%	(41/935)	0.58%	(556/95,589)	0.39%	(190/49,203)
Assessment category: 4	2.35%	(22/935)	0.22%	(209/95,589)	0.15%	(74/49,203)
Assessment category: 5	0.32%	(3/935)	0.03%	(31/95,589)	0.01%	(7/49,203)
Breast density: 0-25%	5.77%	(53/918)	6.77%	(6,453/95,301)	8.61%	(4,234/49,180)
Breast density: 25-50%	43.79%	(402/918)	45.25%	(43,123/95,301)	51.50%	(25,327/49,180)
Breast density: 50-75%	39.76%	(365/918)	31.30%	(29,830/95,301)	36.23%	(17,818/49,180)
Breast density: >75%	4.79%	(44/918)	4.37%	(4,163/95,301)	3.50%	(1,719/49,180)
Breast density: Unknown	5.88%	(54/918)	12.31%	(11,732/95,301)	0.17%	(82/49,180)
Personal history of breast cancer	9.53%	(41/430)	4.64%	(2,724/58,764)	6.11%	(2,100/34,380)
Family history of breast cancer	16.00%	(68/425)	15.84%	(5,974/37,704)	20.15%	(2,056/10,205)
Symptoms reported	1.71%	(4/234)	0.19%	(59/31,536)	0.01%	(1/16,736)

Clinical Demographics for Screening Mammography
January 2020 - March 2020: Comparisons

Age Distribution




Assessment Categories




Clinical Demographics for Screening Mammography
January 2020 - March 2020: Comparisons

Breast Density



History



National Mammography Database QCDR Preview Report

NMD QCDR measures for MIPS participation

This report contains summary information on NMD QCDR measures using your facility's screening data for submission to CMS by NRDR.

For MIPS Quality Category scoring, CMS uses decile benchmarks (1 -10) to compare physicians or groups to peers in order to assign a score for each reported measure. For the NMD QCDR measure preview report, your facility performance scores are ranked against the decile benchmarks and assigned an estimated associated decile rank. Please note that for the 2019 MIPS performance year, CMS has set a measure minimum baseline performance at 3 points, thus the 2020 decile range is 3 - 10.

For the 2019 MIPS performance year, the QCDR measure shown below will be available for MIPS reporting. As a new measure there is no historic benchmark from CMS. NMD registry level decile benchmarks will be calculated if sufficient data is reported. Additionally, CMS may be able to calculate "same year" performance benchmarks for 2020 if sufficient data was reported.

- ACRad 35 Screening Mammography Early Cancer Detection Rate: Percentage of cancers detected at screening mammography that were detected when minimal or node negative

The measure is calculated as such:

Number of cancers that were (a) invasive and node negative, OR (b) invasive and $\leq 10\text{mm}$, OR (c) DCIS, detected at screening mammography.

To learn more about QCDR please go to

<http://www.acr.org/Practice-Management-Quality-Informatics/Registries/Qualified-Clinical-Data-Registry>.

NMD QCDR Measures: Facility 100853
Data for 2020 reporting are exams that were performed in 2019 with follow up through 2020

¹Number of screening exams that qualifies for denominator definition of this measure.

²Number of screening exams that qualifies for numerator definition of this measure.

³Actual score for this measure.

⁴Decile rank against the benchmark available.

Promote your participation in NRDR™!
Download your marketing toolkit today.

acr.org/NMDtoolkit

CONTACT US

1.800.227.5463, ext. 3535

nrd@acr.org | nrd.acr.org

